Yan Feng

发表

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

I. Melero, A. Korman, P. Fracasso, 2019, Clinical Cancer Research.

Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression.

Jingming Zhang, T-G Huang, K. Xie, 2021, International immunopharmacology.

Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs

S. Agrawal, D. Shah, Xiaoning Wang, 2018 .

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

T-G Huang, K. Xie, Yan Feng, 2022, Cancers.

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Jason Zhang, P. Statkevich, Yan Feng, 2019, CPT: pharmacometrics & systems pharmacology.

A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation

Jingming Zhang, Ruiqin Wang, K. Xie, 2021, Breast Cancer Research and Treatment.

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

K. Xie, Yan Feng, Jian-min Fang, 2022, Journal for ImmunoTherapy of Cancer.

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

S. Agrawal, A. Bello, B. Lestini, 2017, Clinical Cancer Research.

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors

S. Agrawal, I. Waxman, P. Statkevich, 2017, Journal of clinical pharmacology.

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

S. Suryawanshi, A. Bello, Xiaoning Wang, 2019, CPT: pharmacometrics & systems pharmacology.

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

D. Berman, S. Parker, E. Masson, 2014, British journal of clinical pharmacology.

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

J. Weber, Tai-Tsang Chen, E. Masson, 2013, Clinical Cancer Research.

Pharmacokinetic and pharmacodynamic modeling for acute and chronic pain drug assessment

Xu Steven Xu, Yan Feng, Haitao Yang, 2014, Expert opinion on drug metabolism & toxicology.

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

T. Owonikoko, Han Chang, Yoon-Koo Kang, 2022, Journal for ImmunoTherapy of Cancer.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

F. D. De Braud, I. Melero, S. Leong, 2020, Clinical Cancer Research.

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

Jason Zhang, H. Vezina, P. Statkevich, 2019, CPT: pharmacometrics & systems pharmacology.

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Diansong Zhou, N. Al-Huniti, Jingyu Yu, 2020, CPT: pharmacometrics & systems pharmacology.

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China

Ziqing Ye, Yu-huan Wang, Ying Huang, 2021, Frontiers in Pediatrics.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

S. Agrawal, G. Kollia, B. Lestini, 2015, Journal of Immunotherapy for Cancer.

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy

S. Agrawal, G. Kollia, B. Lestini, 2015, Journal of Immunotherapy for Cancer.

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma

P. Statkevich, G. Bajaj, Yan Feng, 2017, Journal of clinical pharmacology.

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

A. Bello, Joshua Zhang, Rui Wang, 2019, Journal of Immunotherapy for Cancer.

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

A. Saci, Xiaozhong Qian, R. Moss, 2019, Clinical pharmacology and therapeutics.

Association between immune-checkpoint inhibitor induced tumor shrinkage and overall survival in advanced melanoma and NSCLC.

A. Gupta, S. Agrawal, E. Masson, 2014 .

Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test

Jinfeng Xu, Xu Steven Xu, Min Yuan, 2016, The AAPS Journal.

Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.

A. Gupta, S. Agrawal, G. Kollia, 2012 .

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

V. Ivaturi, V. Goodman, J. Gobburu, 2017 .

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Robert J. Neely, D. Greenawalt, A. Klippel, 2018, Immunology.

Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2016 .

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

S. Agrawal, Xiaoning Wang, G. Bajaj, 2016, CPT: pharmacometrics & systems pharmacology.

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

M. Kudo, A. El-Khoueiry, B. Sangro, 2023, Clinical and translational science.

Quantitative Characterization of the Exposure–Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma

S. Agrawal, A. Yang, B. Lestini, 2016, CPT: pharmacometrics & systems pharmacology.

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

S. Agrawal, A. Bello, B. Lestini, 2017, Clinical Cancer Research.

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

X. Zhao, S. Agrawal, S. Suryawanshi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

S. Agrawal, G. Kollia, B. Lestini, 2015, Journal of Immunotherapy for Cancer.

Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer.

Yan Feng, Amit Roy, Yue Zhao, 2024, British journal of clinical pharmacology.